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PERSPECTIVES_IN CLINCAL NEPHROLOGY
Alport syndrome
Hereditary familial or congenital nephritis is a definite
entity. . . . Deafness is a marked feature in nearly all these
cases... The male members of a family tend to develop
nephritis and deafness and do not as a rule survive. The
females have deafness and hematuria and live to old age...
A. CECIL ALPORT
1927 [1]
In considering the pathogenesis of Alport's syndrome, and
especially in seeking an explanation for the association of
auditoiy, ocular and renal abnormalities, it is a particular
purpose of this communication to point out (I) that the
abnormality may be in a structural gene at a locus govern-
ing the composition of basement membrane in the glomer-
ulus, lens capsule and inner ear, (2) that such a locus may
determine the structure of basement membrane collagen,
and (3) that this serious nephropathy may be a phenotype
reflecting genetic heterogeneity.
GERAI,D S. SPEAR
1973 /2]
These two citations concisely, and for the most part accurately,
summarize the important clinical and genetic features of Alport
syndrome. While the symptoms and natural history of the disease
are somewhat more variable than perceived by Alport, his recog-
nition of the remarkable association of familial nephropathy and
deafness has inspired several generations of investigators to
devote themselves to providing an explanation of the phenome-
non. Spear has been proven correct in every respect, except that it
has turned out that Alport syndrome may arise from mutations at
any of several loci involved in basement membrane (type IV)
collagen synthesis. Alport syndrome can now be understood as a
diffuse disorder of specialized basement membranes, character-
ized by their expression of particular isoforms of type IV collagen.
It is the purpose of this review to present current knowledge about
type IV collagen and its derangements in Alport syndrome, and to
discuss how this information may influence our current and future
clinical practice.
Genetics and biochemistry of type IV collagen
Basement membranes are complex structures composed of
several major and minor glycoprotein constituents. Type IV
collagen is present ubiquitously in basement membranes, where it
is the major collagenous component. Type IV collagen molecules
secreted by endothelial and epithelial cells self-associate into
polygonal networks, which interact with laminin networks, as well
as with entactin, heparan sulfate proteoglycan, and other glyco-
proteins to form basement membranes. Type IV collagen facili-
tates cell attachment to basement membranes, via interactions
with al/31 and a2/31 integrin receptors [3]. Recent studies have
shown that a3f31 may be the principal receptor involved in
glomerular epithelial cell binding to a3(IV), an isoform of type IV
collagen that is highly expressed in glomerular basement mem-
branes [4]. Although normally absent from interstitial areas,
ectopic expression of type IV collagen is a common feature of
interstitial fibrosis.
Type JJ/ collagen n chains
Each type IV collagen molecule is a trimer composed of three
cs chains. Six genetically distinct type IV collagen chains have been
identified, and the genes encoding these chains have been cloned
and sequenced. While the amino acid sequence of each chain is
unique, the chains share basic structural features and show
extensive sequence homology. The major structural features of
a(IV) chains include: a major collagenous domain of about 1400
residues containing the repetitive triplet sequence glycine(Gly)-
X-Y, in which X and Y represent a variety of other amino acids;
a carboxyterminal noncollagenous domain of about 230 residues;
and a noncollagenous aminoterminal sequence of 15 to 20 resi-
dues (Table 1) [5]. Numerous (about 20) interruptions of the
collagenous triplet sequence are present in the major collagenous
domain, while the carboxyterminal noncollagenous domains each
contain 12 completely conserved cysteine residues that participate
in intrachain and interchain disulfide bonds.
Type IV collagen chains form trimers through associations
between their carboxyterminal noncollagenous (NCI) domains,
followed by folding of the collagenous domains into triple helices.
Variable residues within the NCI domains may mediate specificity
of chain association, such as alIa2 or n3/a4 interactions. Type IV
collagen triple helices form networks through several types of
intermolecular interaction. These include end-to-end linkages
between the carhoxyterminal domains of two type IV collagen
triple helices, covalent interactions between four triple helices at
their aminoterminal ends, and lateral associations between triple
helices via binding of the carhoxyterminal domains to sites along
the collagenous region of the triple helix [6, 7]. Disulfide bonds
involving conserved cysteine residues are critical to the interac-
tions between NCI domains. These various linkages between type
IV collagen molecules produce a nonfibrillar polygonal assembly
that serves as a scaffolding for the deposition of other matrix
glycoproteins and for the attachment of cells [8—10].
Type IV collagen genes
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The six type IV collagen genes are arranged in pairs on three
different chromosomes (Fig. 1). Comparison of the peptide
sequences of the six a(IV) chains led Zhou and colleagues to
group them into two classes: ni-like, including the ni, a3 and
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Table 1. Type IV collagen chains
COL4AI 13
COL4A2 13
COL4A3 2
COL4A4 2
COL4A5 X
COL4A6 X
Interruptions in Noncollagenous
collagenous domain
domain (# residues)
21 229
23 227
23 233
26 231
22 229
25 228
Fig. 1. Genomic organization of the six type IV
collagen genes, which are distributed on
chromosomes 13, 2 and X. The regulatory
sequences that modulate the activity of the
COL4AI and COL4A2 genes, and the
transcription factors that bind to these sites, are
also shown. The five exons at the 3' end of
COL4A5, which encode the NC1 domain of
a5(IV), are shaded.
a5(IV) chains; and cs2-Iike, consisting of the a2, a4 and a6(IV)
chains [Ii]. The type IV collagen genes are arranged so that each
al-like gene is paired with an a2-Iike gene. The human al and
a2(IV) chains are encoded by the genes COL4A1 and COL4A2,
respectively, on chromosome 13 [121. COL4A3 and COL4A4
encode the a3 and a4 chains of type IV collagen, respectively.
These genes have been mapped to chromosome 2 [13]. The aS
and a6(IV) chains are respectively encoded by the COL4A5 and
COL4A6 genes on the long arm of the X chromosome [14, 151.
The five exons at the 3' end of each gene encode the carboxyter-
minal noncollagenous domain of the protein product, while most
of the remaining exons encode the collagenous portion.
The 5' ends of each gene pair are adjacent to each other,
separated by sequences of varying length containing motifs in-
volved in the regulation of transpcriptional activity, and the genes
are transcribed in opposite directions. The regulatory machinery
controlling COL4A1/COL4A2 transcription has been extensively
characterized, and may be understood as consisting of two pro-
moters which overlap and operate in opposite directions. This
region contains three functional protein binding sites, including a
novel motif that has been termed a CTC box [16, 171. Sequences
similar to the CTC box occur in the 5' flanking regions of other
genes encoding ECM proteins, including laminin Bi (al), laminin
B2 (yl) and fibronectin, suggesting that regulation of ECM gene
activity may be under the control of a common transcription
factor or family of transcription factors [18j. Activation regions in
the area of the first exon/intron border of each gene are necessary
for transcription of COL4A1 and COL4A2 [19]. A novel sequence
with inhibitory effects on COL4A1 and COL4A2 transcription,
located within intron 3 of the COL4A2 gene, was recently
described [20]. The rate of COL4A1 and COL4A2 transcription in
type IV collagen-producing cells may reflect the relative levels of
promoter and silencer activity.
Some information regarding the regulatory elements of the
COL4A3/COL4A4 and COL4A5/COL4A6 gene pairs is available.
Studies of the murine genes indicate that the promoter elements
of the COL4A3 and COL4A4 genes operate hidirectionally, but
share little sequence homology with the murine COL4AI/
COL4A2 promoter motifs [21]. Like COL4A1/COL4A2, the
intergenic region between COL4A5 and COL4Ao contains a CTC
box [221. The COL4A6 gene is transcribed from two alternative
promoters, resulting in two distinct transcripts, in a tissue-specific
manner [22]. COL4A6 is the only type IV collagen gene for which
such an arrangement has been described.
With the exception of the a3(IV) chain, alternative splicing
does not appear to play an important role in determining type IV
collagen structure in different sites. Alternative splicing of a3(lV)
Chain Gene
al(IV)
a2(IV)
o3(IV)
a4(IV)
a5(IV)
a5(IV)
Collagenous
domain
Chromosome (# residues)
1413
1449
1410
1421
1430
1417
LRE
LD
LAI
Subendothelial
mesangial
(t1(IV)
cx2(IV)
type V collagen
type VI collagen
Epiderrnal BM Bowmans capsule
al(IV), rx2(IV) al(IV), a2(IV)
u5(IV), a6(IV) u3(IV), ct4(IV)
u5(IV), z6(IV)
Kashtan and Michael: A/port syndrome 1447
Table 2. Type IV collagen chain distribution in Alport target organs
Chain Kidney Eye__________ Cochlea Skin
al(IV) all BMs, mesangium all BMs all BMs all BMs
a2(IV) all BMs, mesangium all BMs all BMs all BMs
a3(IV) GBM, BC, dTBM lens capsule
Descemet's memb.
Bruch's memb.
internal limiting memb.
inner/outer sulci
spiral limbus
spiral prominence
basilar memb.
none
a4(IV)
a5(IV)
a6(IV)
GBM, BC, dTBM
GBM, BC, dTBM
BC, dTBM
lens capsule
Descemet's memb.
Bruch's memb.
internal limiting memb.
lens capsule
Descemet's memb.
Bruch's memb.
internal limiting memb.
unknown
inner/outer sluci
spiral limbus
spiral prominence
basilar memb.
inner/outer sluci
spiral limus
spiral prominence
basilar memb.
unknown
none
epidermal BM
epidermal BM
Abbreviations are: BM, basement membrane; GBM, glomerular basement membrane; BC, Bowman's capsule; dTBM, distal
membrane.
tubular basement
Fig. 2. Schematic representation of the
collagenous composition of selected basement
membranes showing a glomerulus at the top and
skin, distal tubular basement membrane (TBM)
and Bowman's capsule at the bottom. Although
the separation of glomerular basement
membrane (GBM) into three distinct layers is
an artifact of fixation for electron microscopy,
both immunofluorescence and immunoelectron
microscopy have localized the a3(IV), a4(IV)
and a5(IV) chains to the central region of the
GBM, while the ul(IV) and 2(IV) chains
occupy a subendothelial position.
prc-mRNA generates at least six transcripts predicting five dis-
tinct proteins, differing in the carhoxyterminal domain [231. The
functional significance of alternative splicing of a3(IV) mRNA is
unclear.
Type IV collagen distribution
Expression of the various type IV collagen chains in human
tissues has been studied using monoclonal and affinity-purified
polyclonal antibodies (Table 2 and Fig. 2) [24—29]. While the
al(IV) and cs2(IV) chains are normally present in all basement
membranes, the a3(IV) and a4(IV) chains exhibit a more re-
stricted distribution. The a3(IV) and a4(IV) chains are highly
expressed in basement membranes that are demonstrably or
potentially involved in Alport syndrome: glomerular basement
membrane, anterior lens capsule, Descemet's membrane, Bruch's
membrane, and several basement membranes of the cochlea. The
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Inheritance
X-linked dominant
X-linked dominant
+ leiomyomatosis
Autosomal recessive
Autosomal dominant'
Locus
COL4A5
COL4AS + COL4A6
COL4A3
COL4A4
COL4A3?
COL4A4?
Table 3. Molecular genetics of Alport syndrome
Affected
gene product
a5(IV)
a5(IV) + a6(IV)
cs3(IV)
a4(IV)
o3(IV)?
___________________________________
a4(IV)?
Linkage of autosomal dominant Alport syndrome to markers on
chromosome 2, in the region of the COL4A3 and COL4A4 gene has been
reported in abstract (JEFFERSON JA, HUGHES AE, Hill. C, MAXWELL. AP,
DOHERTY CC, NEVIN NC: Autosomal dominant Alport syndrome linked
to markers on 2q flanking the COL4A3/COL4A4 genes. Third Interna-
tional Workshop on A/port Syndrome, Erlangen, Germany, Sept. 11—13,
1994).
disparate distributions of sl(IV)/a2(IV) chains and a3(IV)/
a4(IV) chains are accentuated in glomerular diseases such as
diabetic nephropathy and membranous nephropathy [30, 31]. The
complete concordance in distribution between the al(IV) and
a2(IV) chains, on the one hand, and the a3(IV) and 4(IV)
chains on the other hand, suggests that the a3(IV) and a4(IV)
chains may comprise a basement membrane collagen network that
is distinct from the network formed by al(IV) and cs2(IV) chains.
As all basement membranes that express the 3(1V) and a4(IV)
chains also express 5(lV), it appears that the putative a3(IV)/
a4(IV) network contains or associates with 5(lV) as well [25, 27,
321. These immunohistochemical findings are supported by im-
munochemical studies of isolated GBM and lens capsules in which
heterodimers formed by 1(IV) and 2(IV) chains can be sepa-
rated from heterodimers involving the cr3(IV) and a5(IV) chains
[33], and heterodimers consisting of a3(IV) and a4(IV) [34].
The precise structures of these putative separate networks are
as yet unknown. It is not known whether these networks have
different functional characteristics, or whether there are differ-
ences in their interactions with other matrix components or with
cells. It is tempting to speculate that the cs3-cs4-cs5(TV) network
plays a role in selective filtration, based on its expression in
glomerular basement membranes. However, if this is the case,
proteinuria should be an early finding in Alport patients, since this
supposed network is absent from their GBMs (see below).
The a3(IV) chain has been identified as the target of anti-GBM
autoantibodies in Goodpasture syndrome [—371 The Goodpas-
ture epitope resides in the carboxyterminal noncollagenous do-
main of cx3(IV) [38].
Abnormalities of type IV collagen genes and proteins in
Alport syndrome
Two forms of Alport syndrome have been recognized on a
molecular genetic basis: an X-linked dominant form due to
mutations at the COL4A5 locus, primarily affecting the 5(1V)
chain, and an autosomal recessive form arising from mutations at
the COL4A3 locus or the COL4A4 locus (Table 3). Pedigree
analysis suggests that an autosomal dominant type of Alport
syndrome exists, although mutations causing autosomal dominant
disease have yet to be identified [39].
X-linked dominant Alport syndrome
Most patients with Alport syndrome have the X-linked domi-
nant form of the disease. X-linked dominant inheritance was first
suggested by refined analysis of large Alport pedigrees, and
confirmed by mapping of the dominant Alport locus to the long
arm of the X chromosome (Xq22) using analysis of linkage to
polymorphic markers [39—46]. Cloning of a gene (COL4A5) for a
new type TV collagen chain and its mapping to Xq22 was rapidly
followed by demonstration of mutations in COL4A5 in three
Alport kindreds [14, 15, 47, 48]. Numerous mutations in COL4A5,
almost all of which are unique, have been identified since the
initial report; for a relatively up-to-date compilation the reader is
referred to a recent review [49]. However, COL4A5 mutations
have been found in only about 50% of patients with X-linked
Alport syndrome (50—52]. Many of these patients have also been
screened for mutations in the regulatory region immediately
upstream of the 5' end of COL4A5, with negative results [53].
Mutations in COL4A6 have not been found in Alport patients,
except for those with diffuse leiomyomatosis (see below), an
observation that is consistent with the lack of GBM expression of
ca6(IV) normally [28, 29]. Whether there is another gene in the
Xq22 region that might be involved in Alport syndrome, or
whether there are sites in the COL4A5 gene, such as introns,
where cryptic mutations might occur, is currently unknown.
Deletions and other major rearrangements. Major rearrange-
ments at the COL4A5 locus, most of which are deletions, account
for 5.5 to 16% of COL4A5 mutations causing Alport syndrome,
depending on the series; the average incidence seems to be about
8 to 10% [54—58]. Major rearrangements of the COL4A5 appear
to be rare in Japanese Alport patients [52]. Deletions may
encompass the entire COL4A5 gene or occur anywhere within the
gene. A particular type of COL4A5 deletion is observed in
families in which Alport syndrome cosegregates with leiomyomas
of the esophageal tract, tracheobronehial tree and female genital
tract (clinical findings in this condition are described below). All
patients with the Alport syndrome/leiomyomatosis complex sub-
jected to molecular genetic analysis have exhibited deletions of
the 5' end of COL4A5 that extend upstream to involve the first
two exons of COL4A6, with the deletion breakpoint occurring in
the second intron of COL4A6 [50, 59, 60]. Deletions extending
beyond the second intron of COL4A6 are not associated with
leiomyomatosis. The association between 5' deletions of COL4A6
and leiomyomatosis is not presently understood.
Missense and other "small" mutations. Small mutations, such as
missense mutations, splice-site mutations, and deletions of less
than 10 base-pairs, account for the majority of COL4A5 muta-
tions associated with Alport syndrome. A common missense
mutation involves replacement of a glycine residue in the collag-
enous domain of the cs5(IV) chain by another amino acid [52,
61—651. Such mutations are likely to interfere with the normal
folding of the mutant cs5(IV) chain into triple helices with other
cs(IV) chains. Similar mutations in COL1A1, which encodes the
al chain of type I collagen, account for the majority of mutations
causing osteogenesis imperfecta [661. Spontaneous glycine substi-
tutions in a2(IV) are lethal in C. elegans [67]. Other missense
mutations involve critical residues in the earhoxyterminal noncol-
lagenous domain of a5(IV). For example, substitution of serine
for a cysteine residue (Cys1564) in the carboxyterminal noneol-
lagenous domain would prevent formation of a disulfide bond,
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X-linked
Alport syndrome
AutosomalCOL4A5 COL4A5
(major (missense recessive
rearrangement)a and other)a Alport syndrome
ESRD5
Juvenile all most alla
Adult none occasional none
Deafness all most all
before 30 years
Ocular lesions most infrequent ?
a "Major rearrangement" refers to large deletions and other rearrange-
ments of the COL4A5 gene such as inversions and duplications. "Missense
and other" indicates amino acid substitutions, splice-site mutations, small
frame-shifting deletions, and small insertions. "Small" mutations may have
profound effects on the gene product.
ESRD = end-stage renal disease. In Alport families with juvenile
ESRD, the mean age of ESRD in affected males is 31 years or less, while
in families with adult ESRD, the mean age of ESRD in affected males is
greater than 31 years [109].
Only a handful of patients with autosomal recessive Alport syndrome
have been described, making these observations provisional.
which could destabilize heterotrimers or disrupt construction of
networks involving a5(IV) [68]. The conserved arginine residue at
position 1563 is adjacent to Cys1564; replacement of Argi 563 by
glutamine may affect the stability of the disulfide bond [69, 70].
Mutations affecting the sites at which exons are spliced together in
mRNA can result in skipping of a variable number of exons, with
profound effects on the translated protein [70—72]. Several dele-
tions of less than 10 base-pairs that result in shifts of the
transcriptional reading frame have been reported [73, 74], as well
as small insertions that either disrupt or preserve the reading
frame [70, 75].
Autosomal recessive Alport syndrome
The existence of an autosomal recessive variety of Alport
syndrome was suspected for several years, based on pedigree
analyses carried out by French investigators [39]. In several of
these families, involvement of COL4A5 was excluded by demon-
strating the failure of the disease to cosegregate with polymorphic
dinucleotide repetitive sequences within COL4A5 [76]. Eventu-
ally, mutations in the COL4A3 gene on chromosome 2 were
found in two Alport kindreds with autosomal recessive disease,
and in COL4A4 in two other kindreds, by Moehizuki and col-
leagues [77]. Several other examples of COL4A3 mutations
causing autosomal recessive Alport syndrome have been reported
[78—80].
The COL4A3 mutations reported to date were found in the 3'
end of the gene. Two of these mutations are small deletions (5 and
7 base-pairs) that produce a shift of the reading frame and would
thereby prevent translation of the carboxyterminal noncollag-
enous domain of the 3(IV) chain [77, 79]. Two other mutations
would introduce premature stop codons, with the same effect on
the translational product [77, 78]. Knebelmann et al have reported
a COL4A3 mutation that results in the insertion of 74 base-pairs
of extraneous sequence into the a3(IV) mRNA [80].
Of the reported mutations in COL4A4, one would substitute
serine for a glycine residue in the collagenous domain, potentially
GBM BC dTBM EBM
— — — normally absent
— — —
normally absent
— —
-
normally absent
— — — normally absent
— + + +
In some kindreds with Alport syndrome, staining of basement mem-
branes for type IV collagen chains is entirely normal. Therefore, a normal
result does not exclude a diagnosis of Alport syndrome.
Abbreviations are: GBM, glomerular basement membrane; BC, Bow-
man's capsule; dTBM, distal tubular basement membrane; EBM, epider-
mal basement membrane.
impairing folding of the mutant chain into triple helical molecules
[77]. The other mutation introduces a stop codon into the
collagenous domain [77].
Autosomal recessive Alport syndrome should be suspected
when an individual exhibits the typical clinical and pathologic
features of the disease but lacks a positive family history, espe-
cially when a young female has findings indicative of severe
disease such as deafness, renal insufficiency, or nephrotie syn-
drome. Sporadic cases of Alport syndrome may, however, repre-
sent de novo mutations at the COL4A5 locus or a germ-line
COL4A5 mutation in the proband's mother [81].
Phenolype-genolype correlations in A Iport syndrome
X-linked Alport syndrome. Most of the mutations identified in
patients with X-linked Alport syndrome have been associated with
sensorineural deafness and progression to end-stage renal disease
during the second or third decade of life (Tables 4 and 5). Male
patients with COL4A5 deletions consistently exhibit early renal
failure and deafness. The Alport syndrome-diffuse leiomylomato-
sis constellation appears to be confined to patients with deletions
involving the 5' ends of both COL4A5 and COL4A6.
Like COL4A5 deletions, most of the small COL4A5 mutations
described thus far are associated with progression to end-stage
renal disease in the second or third decade of life and sensori-
neural deafness. Single amino acid substitutions that alter an
mRNA splice site, leading to exon skipping, or small deletions
that shift the transcriptional reading frame, can clearly produce
such aberrant protein products that a severe phenotype results. As
mentioned above, mutations that replace a glycine residue in the
collagenous domain with another amino acid may prevent normal
folding of the mutant a5(IV) chain into a triple helix. Glycinc,
which lacks a side chain, is the least bulky of the amino acids, and
only glycinc residues are small enough to allow three of them to
fit into the interior of the tightly wound triple helix [82]. The
position of the substituted glycine may influence its ultimate effect
[83]. Some glycine substitutions may entirely prohibit folding into
a triple helix, which would eliminate the a5(IV) chain from
extracellular matrices and most likely produce a severe disease
phenotype, while others may have minimal effect on folding. In
this regard it is interesting that substitution for G1y1143 of a5(IV)
by aspartic acid was associated with early development of end-
stage renal disease, while substitution of this same glycine residue
Table 4. Timing of ESRD and occurrence of deafness and ocular
lesions in Alport kindreds, according to the locus and type of mutation
Table 5. Immunohistochemistry in Alport syndrome
X-linked dominant
cs3(IV)
cs4(IV)
a5(IV)
Autosomal recessive
a3(IV)
a4(IV)
a5(IV)
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by serine resulted in late renal failure. These findings suggest that
the substituting amino acid may also influence the impact of a
glycine replacement [63, 65].
To date, four different COL4A5 mutations have been associ-
ated with late-onset (after the third decade) ESRD. These include
replacement of the glycine residue at position 325 by arginine,
substitution of serine for the glycine residue at position 1143, a 10
base-pair frame-shifting insertion in exon 49, and replacement of
the conserved cysteine at position 1564 by serine [62, 63, 68, 701.
Normal hearing has been described in association with a glycine to
glutamine substitution and a splice site mutation [64, 72].
Autosomal recessive A/port syndrome. Phenotypic information
on patients with autosomal recessive Alport syndrome is as yet
somewhat sparse. Based upon the available data, patients with
COL4A3 mutations appear to progress to end-stage renal disease
before age 30 and to have sensorineural deafness, regardless of
gender (Table 4)177—791
Expression of basement membrane collagen in Alport syndrome
Several studies in the 1980s established that the native kidneys
of male Alport patients failed to bind anti-GBM antibodies from
patients with Goodpasture syndrome or Alport patients with
post-transplant anti-GBM nephritis [84—89]. Such studies helped
to confirm the pathogenetic link between Alport syndrome and
type IV collagen originally hypothesized by Spear [2, 86]. The
availability of antibodies specific for the six type IV collagen a
chains has allowed investigators to examine basement membrane
expression of these chains in depth.
Glomerular basement membranes of males with X-linked Al-
port syndrome usually lack expression of the a3(IV), a4(IV) and
a5(IV) chains but do express the al(IV) and a2(IV) chains [25,
32, 90, 91] (Table 5 and Fig. 3). Women who are heterozygous for
X-linked Alport mutations frequently exhibit stretches of GBM
that fail to express the a3(IV), a4(IV) and a5(IV) chains, while
expression of the al(IV) and a2(IV) chains is preserved [25, 32,
86, 91, 92]. These observations support the existence of at least
two discrete networks of type IV collagen in basement mem-
branes: a ubiquitous network composed of al(IV) and a2(IV),
and a network made up of a3(IV), a4(IV) and a5(IV) that is
restricted in its distribution.
Epidermal basement membranes normally exprcss the a5(IV)
chain, but not the a3(IV) and a4(IV) chains [32] (Table 5). Most
males with X-Iinked Alport syndrome show no expression of
a5(IV) in epidermal basement membrane, while female heterozy-
gotes frequently display mosaicism [32] (Fig. 3 and Table 5). Lens
capsules of some males with X-linked disease do not express the
a3(IV), a4(IV) or a5(IV) chains, while expression of these chains
is normal in other patients [93]. Recent studies have demon-
strated that the a6(IV) chain is not expressed in Bowman's
capsule, TBM or epidermal basement membranes of Alport males
whose basement membranes lack a5(IV) expression [28, 29].
In patients with autosomal recessive Alport syndrome, GBMs
usually show no expression of the a3(IV), a4(IV) or a5(IV)
chains, but a5(IV) is expressed in Bowmans's capsule, distal
tubular basement membranes and epidermal basement mem-
branes [94] (Table 5 and Fig. 3). This pattern of staining may be
used to distinguish the X-linked and autosomal recessive forms of
Alport syndrome.
These observations indicate that a mutation affecting one of the
chains involved in the putative a3-a4-aS (IV) network can
prevent GBM expression not only of that chain but of the other
two chains as well. The mechanism(s) responsible for this phe-
nomenon remains unexplained. In regards to X-linked Alport
syndrome, Reeders has proposed three potential explanations: (1)
a3(IV) and a4(lV) are synthesized normally, but the incorpora-
tion of these chains into GBM is impaired by the mutation in
a5(IV); (2) normal transcription and/or translation of COL4A3
and COL4A4 is prevented by the a5(IV) mutation; (3) a3(IV)
and a4(IV) are synthesized normally and incorporated into GBM,
but immunoreactivity is blocked by the mutation in a5(IV) [95].
That the a3(IV) and a4(IV) chains are truly absent from Alport
GBM was demonstrated by the immunochemical studies of
Kieppel et al [96]. Thorner et al have described reduced renal
cortical mRNA for a3(IV) and a4(IV) in male dogs with Samoyed
hereditary glomerulopathy, a canine form of Alport syndrome
arising from a COL4A5 mutation [97, 98]. On the other hand,
Nakanishi et al found normal levels of a3(IV) and a4(IV)
mRNAs in renal biopsy specimens from males with X-linked
Alport syndrome (Note added in proof). Clearly, further studies
are needed to clarify the impact of COL4A5 mutations on the
transcriptional activities of COL4A3 and COL4A4.
One can hypothesize several ways in which a mutant a5(TV)
chain could prevent a3(IV) and a4(IV) incorporation into GBM,
assuming that these chains must interact with each other in order
to be expressed in GBM (Fig. 4). Failure to form trimers
composed of these chains could result from any COL4A5 muta-
tion that had the effect of preventing normal synthesis or confor-
mation of the carboxyterminal domain of a5(IV), which mediates
chain association. Among these mutations would be large dele-
tions, frame-shift mutations, alterations that produce premature
stop codons, and missense mutations that eliminate conserved
cysteine residues in the carboxyterminal domain. This category of
COL4A5 mutation is represented by Figure 4B. Type IV collagen
a chains that fail to form trimers are presumably degraded intra-
or extracellularly. The other category of mutations include those
that allow initiation of trimer formation, but prevent normal
folding of the collagenous domains of the three chains into a triple
helix (Fig. 4C). The majority of these mutations will consist of
single base-pair substitutions that replace a glycine reside with
another amino acid, as described above. Such mutations in the
COL1A1 and COLI A2 genes in patients with osteogenesis im-
perfeeta result in trimers of al(I) and a2(I) that exhibit enhanced
susceptibility to proteolytie degradation. In this way, a mutant
collagen a chain can bring about the destruction of the normal
chains with which it associates (Prockop has termed this phenom-
enon "procollagen suicide", but in the case of Alport syndrome
"proeollagen fratricide" might be a more appropriate appellation
[99]). In the absence of a3/a5 heterotrimers, a3/a4 heterotrimers
may be prevented from forming networks (Fig. 4D).
At this time there is no direct evidence for post-translational
effects of COL4A5 (or COL4A3, or COL4A4) mutations on
formation of trimers or networks comprising the cr3, cr4 and
a5(IV) chains. However, in vitro studies ongoing in several
laboratories will hopefully begin to provide some insight into this
area.
Pathogenesis of basement membrane lesions in A/port syndrome
It is now apparent that the basement membrane pathology of
Alport syndormc originates in abnormalities of a collagen net-
work composed of the a3, cr4 and aS chains of type IV collagen.
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Fig. 3. Comparison of the collagenous composition of normal and Aiport basement membranes, as determined by indirect immunofluorescence. Glomerular
reactivity is shown in A and skin reactivity is shown in B. In order to conserve space, findngs in females heterozygous for X-linked Alport syndrome are
not shown. The reader is referred to the paper by Nakanishi et al ftr photomicrographs of glomerular mosaicism for cs3(IV) and a5(IV) [911. The reader
is referred to the paper by Gubler and colleagues for photomicrographs of distal tubular basement membrane reactivity for a3(IV) and a5(IV) in
autosomal recessive Alport syndrome
This network is usually absent from the basement membranes of straightforward demonstration of the consequences of abnormal-
Alport patients, although in some patients the network persists ities of this network may be anterior lenticonus, an ocular lesion
but is presumably defective in structure and function. The most that is specific for Alport syndrome. Anterior lenticonus appears
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Hypothetical post-translational effects of
COL4A5 mutation
-
to result from thinning and fragility of the anterior lens capsule
[100, 101]. Some Alport patients with anterior lenticorius show no
expression of the a3, n4 and n5 chains of type IV collagen in their
lens capsules, while in others expression of thesc chains appears is
normal by immunohistochemistry f31•
Hematuria, the first renal manifestation of Alport syndrome,
Fig. 4. Speculation about the possible post-
translational effects of a COL4A5 mutation
resulting in an abnormal a5(IV) chain. These
speculations, which also apply to COL4A3 and
COL4A4 mutations in autosomal recessive
Alport syndrome, are attempts to explain how a
mutation at one of these loci interferes with the
expression of the products of the other two loci
in basement membranes. A. Depiction of what
may be the normal Situation: a5(IV) chains
interact intracellularly with a3(IV) and a4(IV)
chains to form heterotrimers, which are then
secreted and incorporated into GBM. B. A
COL4A5 mutation that prevents synthesis of
cs5(IV), such as a deletion. The a3(IV) and
cs4(IV) chains are unable to form
heterotrimers, and undergo degradation. C.
Possible effects of a missense COL4A5
mutation, such as the replacement of a glycine
residue in the collagenous domain of a5(IV) by
another amino acid: the abnormally folded
heterotrimer undergoes degradation before
incorporation into GBM. D. It is assumed that
a3(IV) forms distinct heterotrimers with o4(IV)
and u5(IV), and that the interaction between
the carboxyterminal noncollagenous (NC1)
domains of these heterotrimers is crucial to the
formation of a3-u4-a5 networks. In this
scenario, the COL4A5 mutation prevents the
normal formation of a3-a5 heterotrimers. The
a3-cr4 hetcrotrimers are unable to participate in
network formation, resulting in their
degradation.
may reflect fragility of the Alport GBM, in which absence of the
collagen network formed by the s3, s4 and cs5 chains of type IV
collagen is associated with GBM thinning and perhaps a tendency
to develop focal ruptures early in life. The inexorable develop-
ment of GBM thickening, proteinuria and renal insufficiency is
less readily explained. Unlike other glomerulopathies, Alport
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syndrome is characterized by the accumulation of the al and a2
chains of type IV collagen along with types V and VI collagen in
GBM [90, 94]. These proteins appear to spread from their normal
subendothelial location in GBM, so that they come to occupy the
full width of GBM. As Alport glomeruli undergo sclerosis, the
crl(IV) and a2(IV) chains disappear from the glomeruli, but type
V and type VI collagen persist and may, in fact, accumulate. It is
possible that the altered expression of the al(IV) and a2(IV)
chains, type V collagen and type VI collagen represents a
compensatory response to the loss of the a3/c4/cr5network from
OBM, or may simply reflect alterations in glomerular cellular
behavior resulting from the absence of the signals provided to
cells by this network. Replacement of the laminin 2 chain by
laminin 1 in the GBM of laminin p2-deficient mice has been
described, providing some basis for suggesting that "molecular
compensation" may account for the aberrant expression of ni(IV)
and n2(IV) chains in Alport GBM [102].
Clinical, laboratory and pathological features of
Alport syndrome
Clinical and laboratory frarures
Renal findings. The cardinal finding of Alport syndrome is
hematuria. Affected males have persistent microscopic hematuria.
Many also have episodic gross hematuria, precipitated by upper
respiratory infections, during the first two decades of life [103].
Hematuria has been discovered in the first year of life in affected
boys, in whom it is probably present from birth [103, 104]. Boys
who are free of hematuria during the first 10 years of life are
unlikely to be affected [103].
Females who are heterozygous for X-linked Alport syndrome
may have intermittent hematuria, and about 10% of obligate
female heterozygotes never manifest hematuria [105]. Hematuria
appears to be persistent in both males and females with autosomal
recessive Alport syndrome. The incidence and pattern of hema-
tuna in individuals who are heterozygous for autosomal disease
have yet to be characterized.
Proteinuria, usually absent in the first few years of life, develops
eventually in males with X-linked disease and in both males and
females with recessive disease. Proteinuria increases progressively
with age, and may eventuate in the nephrotic syndrome [103, 1061.
Significant proteinuria is infrequent in females who are heterozy-
gous for X-linked Alport syndrome.
Hypertension also increases in incidence and severity with age.
Like proteinuria, hypertension is much more likely to occur in
affected males than in affected females in the X-linked form of the
disease, but there are no gender differences in the autosomal
recessive form.
End-stage renal disease (ESRD) develops in virtually all af-
fected males with X-linked Alport syndrome, but the rate of
progression shows significant interkindred variability. Several
authors have observed that the rate of progression to renal failure
is fairly constant among affected males within a particular family
[39, 107, 108], although signficant intrakindred variability in the
rate of progression to renal failure has occasionally been reported
[63, 1031. Alport families can be divided fairly cleanly into those in
which the mean age of ESRD onset in affected males is less or
greater than age 30 [109].
The prognosis in affected females with X-linked Alport syn-
drome is generally benign, with most surviving into old age with
minimal renal disease. Grunfeld and co-workers [110] found that
gross hematunia in childhood, nephrotic syndrome, and diffuse
GBM thickening by electron microscopy were features suggestive
of progressive nephritis in affected females. Sensorineural deaf-
ness and anterior lenticonus were also indicative of an unfavor-
able outcome in affected women. Many of the women with
progressive nephritis maintain adequate renal function until late
in life, that is, 50 to 75 years of age. As in women with other
chronic nephritides, pregnancy does not appear to adversely affect
renal function in those with mild disease, but may be associated
with accelerated loss of function in those with more severe
disease. Both males and females with recessive Alport syndrome
appear likely to progress to ESRD during the second or third
decade of life.
Hearing deficit. Deafness is frequently but not universally asso-
ciated with the Alport renal lesion, occurring in approximately
55% of males and 45% of females with the disease [ill]. In some
families with the Alport nephropathy and apparently normal
hearing, deafness may be a late and very slowly progressive
phenomenon (Note added in proof).
Hearing loss in Alport syndrome is never congenital and usually
becomes apparent by late childhood to early adolescence in boys
with X-linked disease [103]. Hearing impairment in members of
families with Alport syndrome is always accompanied by evidence
of renal involvement [103]. There is no convincing evidence that
deaf males lacking renal disease can transmit Alport syndrome to
their offspring [112]. In its early stages the hearing deficit is
detectable only by audiometry, with bilateral reduction in sensi-
tivity to tones in the 2000 to 8000 Hz range. In affected males the
deficit is progressive and eventually extends to other frequencies,
including those of conversational speech. In females with X-linked
disease hearing loss is less frequent and tends to occur later in life.
There do not appear to be gender differences in the incidence or
course of deafness in autosomal disease.
Studies of brain stem auditory evoked responses implicate the
cochlea as the site of the aural lesion in Alport syndrome [113].
Impaired vestibular function also can be detected [113] but is not
of clinical significance. Only limited information regarding histo-
logic alterations in the cochleae of Alport patients is available,
because of the difficulty in obtaining pathological specimens. The
stnia vascularis appears to be the site of the most striking
histopathologic alterations [114—116].
Ocular defects. Ocular defects, although not as common as
deafness, are not unusual in patients with Alport syndrome,
occurring in 15 to 30% of patients [117, 118]. Anterior lenticonus,
the conical protrusion of the central portion of the lens into the
anterior capsule, is virtually pathognomonic of Alport syndrome.
Nielsen [119] found that all reported patients with anterior
lenticonus who had been adequately examined exhibited evidence
of chronic nephritis and sensorineural deafness. Anterior lentico-
nus is almost entirely restricted to Alport families with rapid
progression to end-stage renal disease (that is, before age 30) and
deafness [109]. Using oblique illumination, anterior lenticonus
appears as a conical or spherical protrusion of the center of the
anterior surface of the lens into the anterior chamber; the base of
the protrusion is circular and measures 2.5 to 4 mm in diameter
[120]. On indirect illumination of the fundus, a dark disc is seen in
the center of the pupillany region; this finding is often referred to
as the "oil droplet in water" effect [1201. The lesion is bilateral in
about 75% of patients [1201. It is far more common in affected
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males but can occur in females [118, 121]. Anterior lenticonus is
absent at birth, usually appearing during the second to third
decade of life [120]. Progressive distortion of the lens may occur,
accompanied by increasing myopia. Lens opacities may be seen in
conjunction with lenticonus, occasionally resulting from rupture
of the anterior lens capsule [122]. Marked attenuation of the
anterior lens capsule in the region of lenticonus has been dem-
onstrated by light and electron microscopy [100, 101], and
Streeten and colleagues also observed numerous vertically-ori-
ented fractures in the anterior lens capsule of a patient with
lenticonus [101].
A variety of other ocular lesions has been reported in patients
with Alport syndrome. Perhaps the most commonly occurring
abnormalities are pigmentary changes in the perimacular region,
consisting of whitish or yellowish granulations surrounding the
foveal area [118, 123—1251. These lesions are frequently accom-
panied by anterior lenticonus but may also occur in the absence of
lenticonus. Govan [121] suggested that these lesions were located
at the level of the internal limiting membrane, the basement
membrane that supports the retinal pigment epithelium. In some
patients, particularly children, disappearance of the foveal reflex
may be the only abnormality observed [103].
Corneal endothelial vesicles (posterior polymorphous dystro-
phy) have been observed in Alport patients by several investiga-
tors [124, 126, 1271. Teekhasaenee and colleagues [127] con-
tended that this may be a fairly frequent finding in Alport
syndrome, indicative of abnormalities in Descemet's membrane,
the basement membrane underlying the corneal endothelium.
Diffuse leiomyomatosis. The association of Alport syndrome
with leiomyomatosis of the esophagus and tracheobronchial tree
has been reported in approximately 20 families [128—131]. Af-
fected females in these kindreds typically exhibit genital leiomyo-
mas as well, with clitoral hypertrophy and variable involvement of
the labia majora and uterus. Bilateral, posterior subcapsular
cataracts also occur frequently in affected individuals in these
kindreds.
Symptoms usually appear in late childhood and include dyspha-
gia, post-prandial vomiting, retrosternal or epigastric pain, recur-
rent bronchitis, dyspnea, cough and stridor. Leiornyomatosis may
be suspected by chest X-ray or barium swallow, and confirmed by
computed tomography or magnetic resonance imaging.
As noted above, all patients with the Alport syndrome-diffuse
leiomyomatosis complex have been found to have deletions that
encompass the 5' ends of the COL4A5 and COL4A6 genes [50,
59, 601. A surprisingly high percentage of these have been shown
to he de novo mutations [1321. In heterozygous females expression
of leiomyomatosis appears to occur more consistently than ex-
pression of the Alport nephropathy [1321.
Hematologic defrcts. The association between hereditary ne-
phritis, deafness and megathrombocytopenia was first reported by
Epstein and coworkers in 1972 [133]. Several other kindreds with
hereditary nephritis, deafness and megathrombocytopenia have
been described since this initial report [134—141]. In most of the
families described, the disorder appears to have been transmitted
as a dominant trait. In the family reported by Parsa and coworkers
there was father-to-son transmission, consistent with an autoso-
mal dominant defect [1351. Three patients with negative family
histories have been reported [134, 138, 1391, possibly representing
new mutations.
Only two reports of this syndrome have included results of
electron microscopy of kidney biopsy specimens. One patient
displayed focal thickening and splitting of the GBM [133], and
GBM thickening and lamellation were present in another [1341.
The association of these platelet and granulocyte abnormalities
with hereditary nephritis remains unexplained. To date there have
been few reports of gene localization or mutation analysis in these
families, except for negative reports regarding COL4A5 involve-
ment [521, so the genetic locus or loci involved remains unknown.
Neither have basement membranes of these patients been exam-
ined for type IV collagen a chain expression.
Renal pathological findings
The renal pathological abnormalities characteristic of Alport
syndrome are discussed in a recent review [142]. There are no
pathognomonic lesions by light microscopy or direct immunoflu-
orescence in Alport syndrome. Indirect immunofluorescence of
type IV collagen a chain expression in renal and/or skin basement
membranes can be diagnostic, as discussed above (Expression of
Basement Membrane Collagen in A/port Syndrome) and below
(Diagnostic Approach) in detail. Electron microscopy frequently
reveals diagnostic abnormalities, which are seen in patients with
and without hearing loss or ocular involvement.
Ultrastructural features. The cardinal fine structural feature of
the kidney in Alport syndrome is the variable thickening, thinning,
basket weaving, and lamellation of the GBM, which is identified in
many but not all affected members of kindreds with Alport
syndrome. Identical morphologic features are apparent in some
patients without a family history of nephritis [143]. Such patients
may represent new COL4A5 mutations, they may be offspring of
asymptomatic female carriers, or may have autosomal recessive
disease.
Ultrastructural alterations of GBM were noted in several
reports of hereditary nephritis in the 1960s [104, 144, 145], but the
significance of the lesions was recognized almost simultaneously
by three laboratories [146 —148]. The most prominent abnormality
is the irregular appearance of the lamina densa, which demon-
strates zones of thickening, thinning, and splitting that may be
interposed with segments of GBM that appear entirely normal.
The abnormalities can affect a portion of a capillary loop, an
entire loop, some or all loops, or can even spare individual
glomeruli [103, 149—151]. The thick segments measure up to 1200
nm [103], usually have irregular outer and inner contours, and are
found more commonly in males than in females [106]. The lamina
densa is transformed into a heterogeneous network of membra-
nous strands, which enclose electron-lucent areas. The electron-
lucent zones may be entirely clear or contain round granules of
variable density that measure between 20 and 90 nm in diameter.
The origin of these granules is unknown, but Rumpelt has
hypothesized that they represent degenerating islands of visceral
epithelial cell cytoplasm [152]. Young children and females, and
adult males on occasion [153], may have diffusely attenuated
segments of GBM measuring as little as 100 nm or less; in some
instances, discontinuities of the GBM have been observed [103,
151, 154]. In these patients, some loops have uniform contours
and a thin but normally textured lamina densa, while other loops
show irregular inner and outer contours with focally lamellated or
split lamina densae. Ruptures of the capillary walls are filled by
endothelial or epithelial cell cytoplasm and may be covered by
newly formed basal lamina material [103, 151]. The altered
capillary walls are typically associated with epithelial foot process
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fusion, which may be extensive even in the absence of significant
proteinuria [103, 147, 155]. The foot process fusion often occurs
along abnormal segments, sparing normal areas of GBM [149].
The specificity of the GBM changes has been questioned [156].
Foci of lamina densa splitting and lamellation were observed in 6
to 15% of specimens in two large series of unselected renal
biopsies [153, 157]. These foci of splitting occur most commonly in
postinfectious glomerulonephritis, focal segmental glomeruloscle-
rosis and hyalinosis, IgA nephropathy, and mesangioproliferative
glomerulonephritis associated with the nephrotic syndrome. For
this reason clinical correlation and immunofluorescence micro-
scopic examination of all biopsies are necessary when Alport
syndrome is the suspected diagnosis. Diffuse thickening and
splitting of GBM is strongly suggestive, if not pathognomonic, of
Alport syndrome [103, 148, 149, 158, 159].
Not all Alport kindreds demonstrate these characteristic ultra-
structural features [148, 158—161]. Thick, thin, normal and non-
specifically altered GBM have all been described. Although
diffuse attenuation of GBM has been considered the hallmark of
benign familial hematuria [162—164], some patients with this
abnormality are members of kindreds with a history of progres-
sion to renal failure [103, 158, 1601. Thus the signficance of an
ultrastructural finding of thin GBMs must be considered in the
context of the family history, basement membrane expression of
type IV collagen n chains, and, at least in some cases (see
Diagnostic Approach, below), genetic information.
It has been suggested that diffuse GBM thinning could be a
forme fruste of Alport syndrome or the first stage of the GBM
alteration, based on the observation that young children and some
women with Alport syndrome often exhibit GBM attenuation,
whereas older individuals have more significant thickening and
basket-weaving [103]. Rumpelt found that the extent of basket-
weaving increased with age in males, whereas in females the GBM
tended to remain attenuated [106]. The possibility that the
overlap between thin GBM disease and Alport syndrome may
amount to more than simply a similarility in appearance was
recently strengthened by the genetic mapping of thin GBM
disease to chromosome 2, in the region of COL4A3 and COL4A4
[165]. On the other hand, GBM expression of the a3, a4 and cs5
chains of type IV collagen in patients with thin GBM disease
appears to be normal [86, 166, 167].
Structural-functional relationships. Rumpelt has described a
correlation between the percent of GBM showing splitting of the
lamina densa and the degree of proteinuria in Alport patients
[106], suggesting that impaired permselectivity may be a func-
tional consequence of the GBM alteration. Kim and colleagues
observed that morphometric parameters such as mesangial vol-
ume fraction, cortical interstitial volume fraction, and percent
global glomerular sclerosis were inversely correlated with creati-
nine clearance in Alport syndrome, while creatinirie clearance and
surface density of peripheral GBM were directly correlated [1681.
Similar relationships have been observed in other diseases, such as
diabetic nephropathy and membranoproliferative glomerulone-
phritis (MPGN). However, patients with Alport syndrome showed
signficantly greater impairment of filtration for any degree of
structural change, in comparison with patients with diabetic
nephropathy or MPGN. This observation suggests that these
morphologic abnormalities only partially account for reductions in
creatinine clearance in Alport syndrome. Decreased conductivity
of water across the altered glomerular capillary wall could con-
tribute to the decrement in filtration.
Special clinical considerations
Diagnostic approach
There are now several approaches that may be taken to
establish a diagnosis of Alport syndrome (Fig. 5). The traditional
and still most widely available method is electron microscopic
examination of renal tissue. The presence of the classic Alport
lesion, thickening and multilamellation of the GBM, predicts a
progressive nephropathy, regardless of family history [143, 169].
This approach has some limitations, however. Ultrastructural
information alone does not establish the mode of transmission in
a particular family. Thus, in a patient with a negative family
history, electron microscopy cannot distinguish de novo X-linked
disease from autosomal recessive disease. In some patients the
biopsy findings may be amibiguous, particularly females and
young patients of either sex. Furthermore, families with progres-
sive nephritis and COL4A5 mutations in association with thin
GBMs have been described, indicating that the classic Alport
GBM lesion is not present in all Alport kindreds.
It is not unusual for the pediatric nephrologist to see a child
with hematuria and discover that multiple relatives also have
hematuria, although none has ever undergone kidney biopsy. The
natural history of the Alport renal lesion (see above) suggests that
older, male subjects are more likely to exhibit diagnostic ultra-
structural abnormalities of GBM. In families with a firm diagnosis
of Alport syndrome, evaluation of individuals with newly-recog-
nized hematuria can be limited to ultrasound of the kidneys and
urinary tract in most instances. In the absence of tumor or
structural anomalies of the urinary tract, a diagnosis other than
Alport syndrome is unlikely.
Immunohistochemistiy. Monoclonal antibodies directed against
the NC1 domain of the a5 chain of type IV collagen have recently
become available [32, 1701, making it possible to reliably evaluate
basement membranes for expression of a5(IV). Absence of the
a5(IV) chain from basement membranes has not been described
in any condition other than Alport syndrome, making this a
diagnostic finding. Since the a5(IV) chain is expressed in the
epidermal basement membrane [32, 91, 170, 171], examination of
skin biopsies by immunofluorescence for expression of a5(IV) is
an additional tool for making a diagnosis of Alport syndrome. In
fact, given a male patient with a positive family history and clinical
features characteristic of Alport syndrome, examination of skin
for a5(IV) expression may obviate the necessity for kidney biopsy.
Unfortunately, a normal result does not exclude the diagnosis,
since in some Alport kindreds with X-linked disease affected
males express a5(IV) in their basement membranes [91, 92].
Heterozygous females frequently express 5(1V) mosaically [32,
91, 92, 171]. While clearly mosaic expression of a5(IV) is diag-
nostic of the carrier state, a normal result does not exclude
heterozygosity.
Renal expression of type IV collagen c chains can serve to
confirm a diagnosis of Alport syndrome, and can in addition
differentiate the X-linked and autosomal recessive forms of the
disease (Table 5). As noted above, in most males with X-linked
Alport syndrome renal basement membranes are devoid of the
3, a4 and s5(IV) chains, while females frequently show
mosaic expression of these chains, most readily observed in
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ALPORTSYNDROME
SUSPECTED
RENAL BIOPSY
CLINICAL FINDINGS FAMILY HISTORY GBM thickening with multi-BASIC sensorineural deafness typical pattern is dominant, lamellation is diagnostic
EVALUATION lenticonus without male-male transmission GBM thinning may be only
perimacular flecks family history may be negative abnormality
IMMUNOHISTOCHEMISTRY GENOMIC ANALYSIS
X-linked: necessary for reliable carrier identification
absence of a5(IV) in skin & prenatal diagnosis
absence of a3(IV), a4(IV) & a5(IV) may be useful when clinical & histologic
A IIIklYu%IE in GBM, TBM, Bowman's capsule findings are equivocalL#UJI.. U I V au&,somal recessive:STUDIES absence of a3(IV) & a4(IV) in GBM,
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absence of a5(IV) from GBM; a5(lV)
is present in TBM, Bowman's capsule,
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Fig. 5. In patients with he,naturia, a diagnosic ofAlport syndrome can usually be established by synthesizing the data den ved from clinical evaluation, pedigree
analysis and renal biopsy with electron microscopy. Immunohistochemistry of skin or kidney can be a very useful adjunctive tool, and skin biopsy may be
the initial diagnostic study of choice. Gcnomic analysis is required for unequivocal identification of the carrier state in asymptomatic individuals and
for prenatal diagnosis.
GBM. In most males and females with autosomal recessive
Alport syndrome, the GBM, Bowman's capsule and distal TBM
show no expression of s3(IV) and a4(IV), while a5(IV) is
expressed in Bowman's capsule and distal TBM but not GBM
[91.
A caveat regarding immunohistochemical analysis for diagnosis
of Alport syndrome is that detection of the n5(IV) chains requires
denaturation of tissues in acid-urea [32, 171]. The same is true for
the a4(IV) chain and, depending upon the antibody used, the
cs3(IV) chain (25, 26]. Some experience with this technique, along
with its regular use, enhances the results of staining. Normal
control tissues should he stained side-by-side with patient tissues
in order to assure antibody activity and adequate tissue prepara-
tion. Other reservations have to do with identification of the
carrier state by immunohistochemistry. First, this designation
depends upon the judgement of the observer, as there are no
quantitative criteria for diagnosing heterozygosity. The observer
should therefore have some experience in viewing these tissues,
and some criteria of his/her own for mosaicism. Second, a female
member of an Alport kindred who does not have hematuria may
still be a carrier, hut is less likely to exhibit detectable mosaicism
than a female with hematuria. Skin biopsy is probably not a good
test for detecting asymptomatic carriers of COL4A5 mutations.
The ability to diagnose Alport syndrome by skin biopsy may
eventually reduce reliance on kidney biopsy for diagnosis of this
disease. Skin biopsy is the initial diagnostic maneuver of choice
when kidney biopsy is excessively risky, such as in patients with
advanced renal insufficiency.
Molecular genetic analysis. Genetic analysis provides the only
means for reliably diagnosing the carrier state in asymptomatic
female members of X-linked Alport kindreds and for making a
prenatal diagnosis of Alport syndrome. There are also clinical
situations in which a firm diagnosis of Alport syndrome cannot be
established, or in which it is not possible to determine the mode
of transmission, despite careful evaluation of the pedigree and
application of the full range of histological methods. In these
situations genetic analysis has the potential to provide informa-
tion essential for determining prognosis and guiding genetic
counselling. The potential consequences of genetic counselling
based upon erroneous determination of the mode of inheritance
are illustrated in a case reported by Turco and colleagues [1721.
The inheritance of Alport syndrome in a family can be determined
by linkage analysis, which does not require identification of a
particular mutation.
At the present time, the routine application of molecular
analysis is limited by both particular and general problems. First,
the sheer size of the type IV collagen loci (> 5(3 exons), combined
with the great variety of mutations, most of which are missense
alterations of a single base-pair, presents a formidable obstacle,
even to those laboratories equipped with automatic sequencing
machines. As a result, screening for Alport mutations is confined
to a handful of research laboratories, and is very time-consuming
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and expensive. Second, the experience of several groups that have
carried out extensive screening for COL4A5 mutations in Alport
kindreds suggests that in a substantial fraction of these families
(as high as 50%) mutations will not be identified [50, 51].
Resolution of this puzzle will enhance the sensitivity of genetic
analysis as a diagnostic tool in patients suspected of having Alport
syndrome. Reimbursement for genetic analysis is another issue
that remains unresolved.
In the future, automation and miniaturization of DNA analytic
techniques may result in a relatively simple, rapid and inexpensive
means of assaying a blood or tissue sample for mutations at
genetic loci relevant to Alport syndrome, replacing other diagnos-
tic methods. For now, genetic analysis is appropriate when there
is ambiguity regarding the diagnosis of Alport syndrome or the
mode of transmission, or when prenatal testing is desired.
Renal transplantation
Post-transplant anti-GBM nephritis. Anti-GBM nephritis involv-
ing the renal allograft is a rare, hut dramatic, manifestation of
Alport syndrome. Data from several transplant centers indicates
an incidence of 3 to 4% in transplanted Alport patients [173—1751.
A sense of the overall clinical impact of post-transplant anti-GBM
nephritis can be derived from the data of the North American
Pediatric Renal Transplant Cooperative Study (NAPRTCS),
which document equivalent allograft survival rates in patients with
familial nephritis, in comparison to patients with other diagnoses
[1761. However, in the minority of affected patients, post-trans-
plant anti-GBM nephritis is typically a catastrophic event. A
profile of the Alport patient who develops post-transplant anti-
GBM nephritis can be constructed by examining 26 cases for
which appropriate data are available. The patient is usually male
(23/26), always deaf (26/26), and likely to have reached ESRD
before the age of 30 (24/25). Since this profile describes the
majority of Alport patients presenting for renal transplantation,
its predictive value is somewhat limited. However, it would appear
that Alport patients with normal hearing or late progression to
ESRD are at very low risk for the development of post-transplant
ariti-GBM nephritis. Females with X-linked Alport syndrome also
appear to be in a low-risk category.
The onset of post-transplant anti-GBM nephritis was within the
first year following transplantation in approximately 75% of cases.
Three-quarters of the allografts failed irreversibly, usually within
a few weeks to months after diagnosis. Treatment with plas-
mapharesis and cyclophosphamide has been of limited benefit.
Anti-GBM nephritis has recurred in 7 of 8 patients who under-
went retranspiantation. Post-transplant anti-GBM nephritis may
recur despite an interval of many years between transplants, and
in the absence of detectable circulating anti-GBM antibodies
prior to retranspiantation. At least one patient who developed
post-transplant anti-GBM nephritis in a second transplant after
losing the first to rejection has been reported [1771.
The target(s) of anti-GBM antibodies in some of these patients
has been determined, with variable results. In several patients,
circulating anti-GBM antibodies or antibodies eluted from the
allograft appear to recognize the NCI domain of the a5(TV) chain
[86, 175, 1781. Other patients exhibit antibodies that target the
a3(IV) NC1 domain [179].
It has been proposed that mutations in the COL4AS gene that
prevent expression of an immunogenic gene product, thereby
preventing the establishment of tolerance for c5(lV), might be
associated with an increased risk for the development of post-
transplant anti-GBM nephritis (1801. Of 14 Alport patients with
post-transplant anti-GBM nephritis examined for a COL4A5
mutation, seven, or 50%, had complete or partial deletions [54,
55, 71, 181, 182], compared with a deletion frequency of at most
16% in the general Alport population [183]. Two point mutations
in COL4A5 have been associated with post-transplant anti-GBM
nephritis: a splice-site mutation in exon 38 [71] and replacement
of the cysteine residue at position 1564 by serine (in Utah family
P, one of whose members developed post-transplant anti-GBM
nephritis) [68, 184]. Although the sample size is small, the data
gathered thus far support the hypothesis that Alport patients who
develop anti-GBM nephritis after renal transplantation are more
likely to carry deletions in the COL4A5 gene than the Alport
population at large.
Females who are heterozygous for COL4A5 mutations would
not be expected to be at risk for the development of post-
transplant anti-GBM nephritis, since the product of the normal
COL4A5 allele would allow establishment of immunologic toler-
ance for a5(IV). Nevertheless, post-transplant anti-GBM nephri-
tis has been reported in two females with Alport syndrome [79,
1751. Both of these women were found to have autosomal
recessive Alport syndrome, due to COL4A3 mutations [77, 79].
Even if it were to prove true that certain COL4A5 mutations
are associated with a higher risk for the development of post-
transplant anti-GBM nephritis, we feel this information is cur-
rently of limited value in planning transplantation. It is clear that
Alport patients with COL4A5 deletions can undergo renal trans-
plantation without developing anti-GBM nephritis [58, 180, 182],
indicating that other factors, presently unknown, must influence
the initiation and elaboration of the immune response to the
allograft. Therefore it appears at this time that the only way to
determine whether a previously untranspianted Alport patient
will develop post-transplant anti-GBM nephritis is to perform the
transplant, although as noted previously certain patients are at
very low risk.
Donor selection. In view of our inability to predict the outcome
of a first renal transplant in any particular Alport patient, whether
or not that patient's mutation has been characterized, and the
typically excellent allograft survival in Alport patients, we recom-
mend the use of living donor organs whenever available. Patients
who have lost kidneys to post-transplant anti-GBM nephritis
should not receive living donor kidneys.
Should women who are heterozygous for COL4A5 mutations
be allowed to serve as kidney donors? Clearly, those with protein-
uria, hypertension, or renal insufficiency will not be allowed to
donate, and the same should apply if any hearing loss is present
[110]. What about heterozygotes with hematuria but normal renal
function and hearing? There is virtually no long-term follow-up
information on the impact of uninephrectomy in such women,
although there does not seem to be a drastic decline in renal
function over the first several years after transplant [185] (C.E.
Kashtan, unpublished observations). The wishes of a heterozygous
woman with asymptomatie microhematuria should he thought-
fully considered, hut we must assume at this time that the risk to
such an individual of ultimately developing significant renal
insufficiency is substantially higher than it is for the usual kidney
donor.
1458 Kashtan and Michael: Alport syndrome
Treatment of Alport syndrome
A demonstrably effective method of slowing the progression of
the Alport nephropathy does not presently exist. There have been
no controlled, prospective trials of pharmacotherapy, for example
with angiotensin converting enzyme inhibitors (ACE!), in Alport
syndrome, although anecdotal experience has been reported
(Note added in proof). In our view a multicenter trial of ACEI
therapy in Alport syndrome, including patients in the early stages
of the disease (hematuria, normal blood pressure, little or no
overt proteinuria) and patients with advanced disease (overt
proteinuria, hypertension) is desireable. Since mesangial expan-
sion and interstitial fibrosis are important features of progression
in Alport syndrome, therapies that retard these processes might
be of benefit in Alport syndrome, despite the persistence of the
underlying defect in type IV collagen.
Gene therapy for Alport syndrome? Although the idea of a
genetic therapy for Alport syndrome might seem outlandish, it is
certainly not as fanciful as it would have seemed just a few years
ago [1861. This change reflects the recent unraveling of the
molecular genetics of Alport syndrome, the tremendous enthusi-
asm for genetic therapies in the biomedical community, and
progress in developing genetic therapies for clinical application.
Genetic therapies for Alport syndrome will have to overcome
what seem to be formidable obstacles (see below), and it will have
to be shown that such therapies are superior to renal transplan-
tation in success rate, expense and morbidity. The availability of
animal models of Alport syndrome, such as canine hereditary
glomerulopathy [98] and transgenic mouse models, should allow
in vivo testing of proposed genetic and pharmacologic therapies
[98].
At this time, there are many more questions than answers in
this area. Some of the questions that will eventually need to be
answered include:
(1) Where does the COL4A5 gene need to be expressed? Glomer-
ular c5(IV) chain appears to be a product of the visceral epithelial
cell, as are the cs3(IV) and a4(IV) chains with which it presumably
associates. Is expression by the podocyte critical to the successful
construction of a3-a4-cá(IV) networks? If so, is there a delivery
system that will direct the COL4A5 expression vector to the
podocyte?
(2) When does the COL4A5 gene need to be expressed? We know
very little about the turnover of these chains in GBM, although
one suspects that it is low. If this is the case, a vector that supports
transient expression might be sufficient, and perhaps superior, to
a vector promoting continuous expression. A corollary issue is the
coordination of COL4A5 transcription with transcription of
COL4A3 and COL4A4. Finally, when in the course of the disease
is it appropriate to intervene with gene therapy? Is there a "point
of no return" in Alport syndrome, beyond which progression to
ESRD cannot be significantly altered?
(3) What proportion of cells need to express the gene? Women
who are heterozygous for COL4A5 mutations would be expected
to express normal a5(IV) chains in 50% of their visceral epithelial
cells, on average. These women generally have adequate renal
function for many years. Thus, it will probably be sufficient to
achieve normal a5(IV) expression in only a portion of an Alport
male's visceral epithelial cells. However, expression in even 40 to
50% of these cells would require an extremely efficient method of
gene transfer.
(4) Will overexpression or ectopic expression of cs5 (IV) be toxic?
Unless a way of specifically targeting visceral epithelial cells is
developed, it is likely that the gene will find its way to a variety of
cell types. What will happen if a5(IV) is expressed by these cells?
For example, endothelial expression might produce intimal fibro-
sis; fibroblast expression could result in interstitial fibrosis in any
organ.
(5) Will the COL4A5 gene product be immunogenic? The
example of post-transplant anti-GBM nephritis suggests that in
some patients, expression of normal a5(IV) could result in
anti-GBM nephritis.
(6) Does the expression of the mutant COL4A5 gene need to be
suppressed? If certain mutant cr5(IV) chains induce the destruc-
tion of a3(IV) and cs4(IV) chains (see above), it may be necessary
to suppress the transcription of the mutant gene in order for the
introduced gene to achieve a beneficial effect. It is possible that
expression of the normal gene will itself suppress the mutant gene.
(7) How will therapeutic efficacy be evaluated? Even in patients
with juvenile ESRD, the clinical progression of Alport syndrome
is slow. Both clinical and serial histological measurements may be
needed to evaluate efficacy.
We do not intend that this catalogue of our uncertainties should
suppress enthusiasm for genetic approaches to the treatment of
Alport syndrome. In fact, we expect that research in this area will
illuminate many murky regions in basement membrane biology.
Conclusions
Research in Alport syndrome has established the fundamental
pathobiology of the disease. It is a genetic disorder of type IV
collagen that disrupts the structure and function of glomerular
basement membranes, as well as some basement membranes of
the eye and cochlea. Despite this basic understanding, many
features of the disease remain unexplained, and no effective
therapy, other than renal transplantation, has been developed.
Alport syndrome promises to be an exciting area of investigation
for biologists and clinicians for many years to come.
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Note added in proof
In reference to COL4A5 mutations associated with late development of
ESRD and deafness, Barker and colleagues recently described the substi-
tution of the leucine residue at position 1649 in the carhoxyterminal
noncollagenous domain by arginine (BARKER DF, PRIJCHNO CJ, JIANG X,
ATKIN C, SIONE EM, DENISON JC, FAIN PR, GREGORY MC: A mutation
causing Alport syndrome with tardive hearing loss is common in the
western United States. Am J Hum Genet 58:1157—1165, 1996). Nakanishi
and colleagues assessed o3(IV) and a4(IV) mRNA levels in kidney
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biopsies from males with COL4A5 mutations, using RT-PCR (NAKANISHI
K, Y0sHIKAwA N, IDIMA K, NAKAMURA H: Expression of type IV collagen
a3 and o4 chain mRNA in X-linked Alport syndrome. JAm Soc Nephrol
7:938—945, 1996). Treatment of three patients with hereditary nephritis
with angiotensin-converting enzyme inhibition is described in COHEN EP,
LEMANN J: In hereditary nephritis angiotensin-converting enzyme inhibi-
tion decreases proteinuria and may slow the rate of progression. Am J
Kidney Dis 27:199—203, 1996.
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